# GLP-1 Drugs May Trigger Muscle Loss and Frailty in Older Adults
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) carry a hidden risk for adults over 65. Recent research shows these popular weight-loss medications may accelerate muscle loss and increase frailty in older populations, a concern that extends beyond typical side effects like nausea or injection-site reactions.
The issue stems from how these drugs work. GLP-1 medications suppress appetite so effectively that older adults often consume less protein alongside their weight loss. This combination creates a dangerous scenario. When the body loses weight rapidly without adequate protein intake, it sheds muscle mass along with fat. For seniors already at risk of age-related muscle decline (sarcopenia), this effect compounds the problem.
Dr. Fatima Cody Stanford, obesity specialist at Massachusetts General Hospital, emphasizes that older patients need close monitoring. "Rapid weight loss without proper nutrition support can leave seniors weak and vulnerable to falls and injuries," Stanford notes. The concern parallels findings from bariatric surgery research, where aggressive weight loss without intervention led to functional decline in older patients.
Experts recommend that adults over 65 on GLP-1 drugs maintain high protein intake (1.0 to 1.2 grams per kilogram of body weight daily), engage in regular resistance training, and work with registered dietitians during treatment. Regular strength assessments help catch muscle loss early.
The American Geriatrics Society and Endocrine Society now suggest screening older patients for baseline muscle function before starting GLP-1 therapy. Family members should watch for warning signs: increased difficulty climbing stairs, slower walking speed, or trouble rising from chairs.
GLP-